Report Reveals TrumpRx Fails to Halt Rising Drug Prices
The Trump administration launched the TrumpRx website in February 2026. The platform aimed to narrow U.S. drug prices with other wealthy nations.
A report reveals that TrumpRx has failed to halt many rising drug prices. Early analyses show mixed and limited consumer benefits.
Price comparisons with the UK system
A March analysis by Filmogaz.com compared TrumpRx listings with public NHS data. Many medicines still cost less under England’s system.
England uses a fixed prescription charge per item. The U.S. system varies by insurance, manufacturer deals, and retail pricing.
Some high-demand treatments, such as obesity drugs, became cheaper for certain Americans. Several widely used medicines remained substantially more expensive.
Findings from the Senate-linked review
Separate reporting by Filmogaz.com, citing a Senate Democrats’ report, found price increases on hundreds of medicines. These included drugs for cancer and chronic illnesses.
Companies with pricing agreements still raised costs on many products. The report also noted costly launches of new therapies.
Some new medicines now have annual price tags in the hundreds of thousands of dollars. Lawmakers and advocates called the trend alarming.
Voices from policymakers and experts
Senator Ron Wyden criticized the program as akin to a “glorified coupon book.” He said the platform helps out-of-pocket buyers more than insured patients.
Senator Bernie Sanders said Americans still pay far higher drug prices than people elsewhere. He argued most patients have seen little improvement.
Health policy researcher Stacie Dusetzina of Vanderbilt warned that deal details lack transparency. She said unclear terms may blunt patient savings.
Tariff proposal and industry response
The administration proposed tariffs on imports from firms that reject Most-Favoured-Nation pricing terms. Officials said the move would boost domestic production.
Economists at ING warned tariffs could raise costs. They said generics may become pricier if components face new import charges.
Smaller and mid-sized manufacturers said adapting will be difficult. They worried that extra expenses would be passed to consumers.
Outlook and remaining uncertainties
Initial evidence shows TrumpRx has delivered targeted savings for some patients. It has not produced wide-ranging price reductions.
Reports highlight ongoing price increases across many drug classes. Transparency, long-term impact, and affordability remain open questions.
As policy measures evolve, the U.S. market will likely stay complex. Costs will continue to vary by how and where medicines are purchased.
